# Treat-to-target With Secukinumab in Axial Spondyloarthritis

> **NCT03639740** · PHASE4 · UNKNOWN · sponsor: **Professor Mikkel Østergaard** · enrollment: 88 (estimated)

## Conditions studied

- Axial Spondyloarthritis
- Ankylosing Spondylitis

## Interventions

- **DRUG:** Secukinumab 150 milligram [Cosentyx]

## Key facts

- **NCT ID:** NCT03639740
- **Lead sponsor:** Professor Mikkel Østergaard
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-15
- **Primary completion:** 2021-02
- **Final completion:** 2021-02
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2019-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03639740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03639740, "Treat-to-target With Secukinumab in Axial Spondyloarthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03639740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*